<DOC>
	<DOCNO>NCT01662284</DOCNO>
	<brief_summary>The purpose study ass use investigational compound 124I-NM404 accurate detection characterization wide variety solid primary metastatic malignancy anywhere body .</brief_summary>
	<brief_title>Study 124I-NM404 Advanced Solid Malignancies</brief_title>
	<detailed_description>124I-NM404 new investigational agent develop good identify local tumor cancerous tumor use image technology positron emission tomography ( PET ) scan . An investigational drug drug approve Food Drug Administration ( FDA ) available research use . 124I-NM404 take cancer cell , normal cell . Compared traditional method CT ( compute tomography ) MRI ( Magnetic resonance imaging ) , 124I-NM404 may help physician accurately see evaluate cancerous tumor . This agent safely study animal limit number human patient lung cancer . This study do determine best dose use fully evaluate image result use new agent .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Diagnosis advance solid malignancy . Allowed tumor type : triple negative breast , prostate , colorectal , gastric , ovarian , pancreatic , esophageal , soft tissue sarcoma , head &amp; neck cancer Disease must least 1cm diameter Brain metastasis must stable least one month . ECOG performance status 02 Anticipated survival le 5 year , per treat physician Skin lesion Chemotherapy radiotherapy within 1 week Residual toxicity grade 2 great prior therapy Adequate organ function per specify laboratory parameter Platelet count &gt; = 75,000/uL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>